

National Institute for Health and Care Excellence

Final

Rheumatoid Arthritis (update)

NICE guideline: acknowledgments

NICE guideline NG100

Authors and contributors

July 2018

Final

*Developed by the National Guideline Centre,
hosted by the Royal College of Physicians*

Disclaimer

The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or service users. The recommendations in this guideline are not mandatory and the guideline does not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and, where appropriate, their carer or guardian.

Local commissioners and providers have a responsibility to enable the guideline to be applied when individual health professionals and their patients or service users wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with compliance with those duties.

NICE guidelines cover health and care in England. Decisions on how they apply in other UK countries are made by ministers in the [Welsh Government](#), [Scottish Government](#), and [Northern Ireland Executive](#). All NICE guidance is subject to regular review and may be updated or withdrawn.

Copyright

© NICE [2018]. All rights reserved. Subject to Notice of rights.

Contents

1	Guideline developers	5
1.1	Members of the NICE guideline committee.....	5
1.2	Members of the National Guideline Centre technical team	5
1.3	Co-optees.....	6
1.4	Acknowledgements	6

1 Guideline developers

1.1 Members of the NICE guideline committee

Name	Role
Stephen Ward (Chair)	Consultant in Pain Medicine, Brighton and Sussex University Hospitals NHS Trust
Frank McKenna (Clinical Lead)	Consultant Rheumatologist, Trafford General Hospital, Central Manchester Foundation Trust
Ann Bevan	GP (retired)
Ailsa Bosworth	Lay member
Victoria Chamberlain	Rheumatology Nurse Specialist, Trafford Hospital, Central Manchester Foundation Trust
Jennie Jones	Lay member
Bruce Kirkham	Consultant Rheumatologist, Guy's & St Thomas' NHS Foundation Trust
Hilary McKee	Consultant Pharmacist
Anupama Nandagudi	Consultant Rheumatologist, Basildon and Thurrock University Hospital NHS Trust
Benjamin Parker	Consultant Rheumatologist, Kellgren Centre for Rheumatology, Manchester Royal Infirmary
Heidi Siddle	Consultant Podiatrist, Leeds Teaching Hospitals NHS Trust and Associate Professor, University of Leeds
Louise Warburton	GP with special interest in Musculoskeletal Medicine, Telford Musculoskeletal Service

1.2 Members of the National Guideline Centre technical team

Name	Role
Alex Allen	Senior Research Fellow
Joanna Ashe	Senior Information Specialist (until May 2017)
Kate Ashmore	Document Editor/Process Assistant (from October 2017)
Serena Carville	Guideline Lead
Jill Cobb	Information Specialist (from May 2017)
Meredith Faust	Document Editor/Process Assistant (until October 2017)
Lefteris Floros	Senior Health Economist (until February 2017)
Lina Gulhane	Information Specialist Lead (from May 2017)
Amy Kelsey	Senior Project Manager (from October 2017)
Sophia Kemmis-Betty	Senior Health Economist (from February 2017)
Ben Pordes	Senior Project Manager (until October 2017)
Jacqui Real	Senior Research Fellow (until November 2017)
Grit Scheffler-Ansari	Research Fellow (January 2017 – July 2017)

1 **1.3 Co-optees**

2 These experts advised the committee on parts of the guideline, but did not contribute to
3 writing the evidence reports or formulating recommendations.

4

Name	Role
Amanda Isaac	Consultant MSK Radiologist, Guy's & St Thomas' Hospital

5 **1.4 Acknowledgements**

6 The development of this guideline was assisted by Rebecca Boffa, Jessica Glen, Lina
7 Gulhane, Martin Harker, Kate Lovibond, Joseph Runicles and Natalie Wood from the NGC
8 and Glen Hazelwood, Jordi Pardo Pardo and Peter Tugwell from Cochrane Musculoskeletal.

9 The systematic reviews of the clinical and cost effectiveness of DMARDS in people with
10 rheumatoid arthritis who are DMARD naïve (evidence review F) were greatly assisted by
11 Cochrane Musculoskeletal. This review was completed collaboratively and data were shared
12 between the two centres for this review.